Scutellarein inhibits RANKL-induced osteoclast formation in vitro and prevents LPS-induced bone loss in vivo

Fangsheng Fu, Siyuan Shao, Ziyi Wang, Fangming Song, Xixi Lin, Jiaxin Ding, Chen Li, Zuoxing Wu, Kai Li, Yu Xiao, Yiji Su, Jinmin Zhao, Qian Liu, Jiake Xu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Osteoporosis, arthritis, Peget's disease, bone tumor, periprosthetic joint infection, and periprosthetic loosening have a common characteristic of osteolysis, which is characterized by the enhanced osteoclastic bone resorptive function. At present, the treatment target of these diseases is to interfere with osteoclastic formation and function. Scutellarein (Scu), a flavonoids compound, can inhibit the progress of tumor and inflammation. However, the role of Scu in inflammatory osteolysis isn’t elucidated clearly. Our study showed that Scu inhibited bone destruction induced by LPS in vivo and OC morphology and function induced by RANKL in vitro. Mechanistic studies revealed that Scu suppressed osteoclastic marker gene expression by RANKL-induced, such as Ctsk9, Mmp9, Acp5, and Atp6v0d2. In addition, we found that the inhibition effects of osteoclastogenesis and bone resorption function of Scu were mediated via attenuating NF-κB and NFAT signaling pathways. In conclusion, the results showed that Scu may become a potential new drug for the treatment of inflammatory osteolysis.

Original languageEnglish
Pages (from-to)11951-11959
Number of pages9
JournalJournal of Cellular Physiology
Volume234
Issue number7
DOIs
Publication statusPublished - 1 Jul 2019

Fingerprint

Osteoclasts
Bone
Bone and Bones
Osteolysis
Tumors
Bone Diseases
Bone Resorption
Flavonoids
Osteogenesis
Gene expression
Osteoporosis
Arthritis
scutellarein
In Vitro Techniques
Neoplasms
Joints
Inflammation
Gene Expression
Infection
Pharmaceutical Preparations

Cite this

Fu, Fangsheng ; Shao, Siyuan ; Wang, Ziyi ; Song, Fangming ; Lin, Xixi ; Ding, Jiaxin ; Li, Chen ; Wu, Zuoxing ; Li, Kai ; Xiao, Yu ; Su, Yiji ; Zhao, Jinmin ; Liu, Qian ; Xu, Jiake. / Scutellarein inhibits RANKL-induced osteoclast formation in vitro and prevents LPS-induced bone loss in vivo. In: Journal of Cellular Physiology. 2019 ; Vol. 234, No. 7. pp. 11951-11959.
@article{467ade6e9f434e8389b8f436eba24c9d,
title = "Scutellarein inhibits RANKL-induced osteoclast formation in vitro and prevents LPS-induced bone loss in vivo",
abstract = "Osteoporosis, arthritis, Peget's disease, bone tumor, periprosthetic joint infection, and periprosthetic loosening have a common characteristic of osteolysis, which is characterized by the enhanced osteoclastic bone resorptive function. At present, the treatment target of these diseases is to interfere with osteoclastic formation and function. Scutellarein (Scu), a flavonoids compound, can inhibit the progress of tumor and inflammation. However, the role of Scu in inflammatory osteolysis isn’t elucidated clearly. Our study showed that Scu inhibited bone destruction induced by LPS in vivo and OC morphology and function induced by RANKL in vitro. Mechanistic studies revealed that Scu suppressed osteoclastic marker gene expression by RANKL-induced, such as Ctsk9, Mmp9, Acp5, and Atp6v0d2. In addition, we found that the inhibition effects of osteoclastogenesis and bone resorption function of Scu were mediated via attenuating NF-κB and NFAT signaling pathways. In conclusion, the results showed that Scu may become a potential new drug for the treatment of inflammatory osteolysis.",
keywords = "NF-κB, NFATc1, osteoclast (OC), osteolysis, scutellarein (Scu)",
author = "Fangsheng Fu and Siyuan Shao and Ziyi Wang and Fangming Song and Xixi Lin and Jiaxin Ding and Chen Li and Zuoxing Wu and Kai Li and Yu Xiao and Yiji Su and Jinmin Zhao and Qian Liu and Jiake Xu",
year = "2019",
month = "7",
day = "1",
doi = "10.1002/jcp.27888",
language = "English",
volume = "234",
pages = "11951--11959",
journal = "Journal Cellular Physiology",
issn = "0021-9541",
publisher = "John Wiley & Sons",
number = "7",

}

Fu, F, Shao, S, Wang, Z, Song, F, Lin, X, Ding, J, Li, C, Wu, Z, Li, K, Xiao, Y, Su, Y, Zhao, J, Liu, Q & Xu, J 2019, 'Scutellarein inhibits RANKL-induced osteoclast formation in vitro and prevents LPS-induced bone loss in vivo' Journal of Cellular Physiology, vol. 234, no. 7, pp. 11951-11959. https://doi.org/10.1002/jcp.27888

Scutellarein inhibits RANKL-induced osteoclast formation in vitro and prevents LPS-induced bone loss in vivo. / Fu, Fangsheng; Shao, Siyuan; Wang, Ziyi; Song, Fangming; Lin, Xixi; Ding, Jiaxin; Li, Chen; Wu, Zuoxing; Li, Kai; Xiao, Yu; Su, Yiji; Zhao, Jinmin; Liu, Qian; Xu, Jiake.

In: Journal of Cellular Physiology, Vol. 234, No. 7, 01.07.2019, p. 11951-11959.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Scutellarein inhibits RANKL-induced osteoclast formation in vitro and prevents LPS-induced bone loss in vivo

AU - Fu, Fangsheng

AU - Shao, Siyuan

AU - Wang, Ziyi

AU - Song, Fangming

AU - Lin, Xixi

AU - Ding, Jiaxin

AU - Li, Chen

AU - Wu, Zuoxing

AU - Li, Kai

AU - Xiao, Yu

AU - Su, Yiji

AU - Zhao, Jinmin

AU - Liu, Qian

AU - Xu, Jiake

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Osteoporosis, arthritis, Peget's disease, bone tumor, periprosthetic joint infection, and periprosthetic loosening have a common characteristic of osteolysis, which is characterized by the enhanced osteoclastic bone resorptive function. At present, the treatment target of these diseases is to interfere with osteoclastic formation and function. Scutellarein (Scu), a flavonoids compound, can inhibit the progress of tumor and inflammation. However, the role of Scu in inflammatory osteolysis isn’t elucidated clearly. Our study showed that Scu inhibited bone destruction induced by LPS in vivo and OC morphology and function induced by RANKL in vitro. Mechanistic studies revealed that Scu suppressed osteoclastic marker gene expression by RANKL-induced, such as Ctsk9, Mmp9, Acp5, and Atp6v0d2. In addition, we found that the inhibition effects of osteoclastogenesis and bone resorption function of Scu were mediated via attenuating NF-κB and NFAT signaling pathways. In conclusion, the results showed that Scu may become a potential new drug for the treatment of inflammatory osteolysis.

AB - Osteoporosis, arthritis, Peget's disease, bone tumor, periprosthetic joint infection, and periprosthetic loosening have a common characteristic of osteolysis, which is characterized by the enhanced osteoclastic bone resorptive function. At present, the treatment target of these diseases is to interfere with osteoclastic formation and function. Scutellarein (Scu), a flavonoids compound, can inhibit the progress of tumor and inflammation. However, the role of Scu in inflammatory osteolysis isn’t elucidated clearly. Our study showed that Scu inhibited bone destruction induced by LPS in vivo and OC morphology and function induced by RANKL in vitro. Mechanistic studies revealed that Scu suppressed osteoclastic marker gene expression by RANKL-induced, such as Ctsk9, Mmp9, Acp5, and Atp6v0d2. In addition, we found that the inhibition effects of osteoclastogenesis and bone resorption function of Scu were mediated via attenuating NF-κB and NFAT signaling pathways. In conclusion, the results showed that Scu may become a potential new drug for the treatment of inflammatory osteolysis.

KW - NF-κB

KW - NFATc1

KW - osteoclast (OC)

KW - osteolysis

KW - scutellarein (Scu)

UR - http://www.scopus.com/inward/record.url?scp=85058367376&partnerID=8YFLogxK

U2 - 10.1002/jcp.27888

DO - 10.1002/jcp.27888

M3 - Article

VL - 234

SP - 11951

EP - 11959

JO - Journal Cellular Physiology

JF - Journal Cellular Physiology

SN - 0021-9541

IS - 7

ER -